EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

HIV capsid inhibitors: Mechanisms, resistance, and therapeutic advances

Mohamed Mahdi iD, Botond Lakatos, János András Mótyán, Gyula Hoffka, József Tőzsér

PLOS Pathogens · 10.07.2026 · 22 (7) · e1014361

DOI: 10.1371/journal.ppat.1014361 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PLOS Pathogens, online erschienen am 10.07.2026. Verfasst von Mohamed Mahdi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. Hauptthemen laut MEDLINE: Drug Resistance, Viral, HIV-1, HIV Infections, Anti-HIV Agents. Die Arbeit nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Thematic Excellence Programme, János Bolyai Research Scholarship of the Hungarian Academy of Sciences, University Research Fellowship program of the Ministry for Culture and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The capsid (CA) of the human immunodeficiency virus (HIV) has emerged as a critical therapeutic target owing to its essential roles in viral replication, nuclear import, and integration. Capsid inhibitors (CIs) disrupt these processes by binding to highly conserved structural interfaces, offering a novel mechanism distinct from enzyme-targeting antiretrovirals. In this review, we summarize the molecular architecture of the HIV-1 CA and its interactions with host factors, and we compare key structural and functional differences between HIV-1 and HIV-2. We provide an overview of established and investigational CIs, explore the resistance-associated mutations, their structural basis, and their impact on inhibitor potency, alongside insights into cross-resistance patterns. Special emphasis is placed on lenacapavir, exploring data from pivotal trials and emerging applications in both treatment and prevention, including long-acting pre-exposure prophylaxis (PrEP). Moreover, we highlight future perspectives, including the need for global surveillance of CA polymorphisms, strategies to overcome resistance, and challenges in accessibility and cost-effectiveness in resource-limited settings. Collectively, CIs represent a transformative addition to the HIV therapeutic arsenal, though their optimal deployment requires careful consideration of efficacy, resistance, and implementation barriers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, ViralHIV-1HIV InfectionsAnti-HIV AgentsCapsid ProteinsCapsidHIV-2HumansVirus Replication

Substanzen

Anti-HIV AgentsCapsid Proteins

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Department of Infectology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Department of Hematology and Infectious Diseases, Departmental Group of Infectious Diseases, Semmelweis University, Budapest, Hungary.
  • Department of Chemistry, Lund University, Lund, Sweden.

ORCID-Profile: Mohamed Mahdi

Förderung

  • Thematic Excellence Programme
  • János Bolyai Research Scholarship of the Hungarian Academy of Sciences
  • University Research Fellowship program of the Ministry for Culture and Innovation
  • Innovációs és Technológiai Minisztérium
  • Hungarian Academy of Science

Zitieren

APA

Mahdi, M., Lakatos, B., Mótyán, J. A., Hoffka, G., & Tőzsér, J. (2026). HIV capsid inhibitors: Mechanisms, resistance, and therapeutic advances. PLOS Pathogens, 22(7), e1014361. https://doi.org/10.1371/journal.ppat.1014361

Vancouver

Mahdi M, Lakatos B, Mótyán JA, Hoffka G, Tőzsér J. HIV capsid inhibitors: Mechanisms, resistance, and therapeutic advances. PLOS Pathogens. 2026;22(7):e1014361. doi:10.1371/journal.ppat.1014361

BibTeX
@article{Mahdi2026,
  author = {Mahdi, Mohamed and Lakatos, Botond and Mótyán, János András and Hoffka, Gyula and Tőzsér, József},
  title = {HIV capsid inhibitors: Mechanisms, resistance, and therapeutic advances},
  journal = {PLOS Pathogens},
  year = {2026},
  volume = {22},
  number = {7},
  pages = {e1014361},
  doi = {10.1371/journal.ppat.1014361}
}
Kostenlos starten →